Download Now - The Burrill Report

PIPELINEThe Burrill Report❱❱ (continued)Patents Announced in September 2012COMPANY TICKER COMPANY DESCRIPTION GRANTINGAGENCYHorizon Pharma Nasdaq:HZNP A biopharmaceutical companythat is developing andcommercializing medicinesto target unmet therapeuticneeds in arthritis, pain andinflammatory diseasesU.S. Patent andTrademark OfficePATENT NUM-BERNotices of AllowancePATENT COVERSCovers Duexis (ibuprofen andfamotidine) tablets. Duexis isindicated for the relief of signs andsymptoms of rheumatoid arthritisand osteoarthritis and to decreasethe risk of developing upper gastrointestinalulcers.Alitair PharmaceuticalsPrivateCompany manufactures andmarkets respiratory drugs,offering asthma/ chronicobstructive pulmonary diseaseand over-the-counter coughproductsU.S. Patent andTrademark OfficeNotice of AllowancePatent covers company’s ion exchangeresin formulation of benzonatate.The patent includes specificclaims for reducing or eliminatingthe choking hazard associated withconventional liquid formulations ofbenzonatate.Rexahn PharmaceuticalsNYSE AMEX:RNNA clinical stage pharmaceuticalcompany developing andcommercializing first in classand market leading therapeuticsfor cancer, CNS disorders,sexual dysfunction and otherunmet medical needsEuropean PatentOfficeEuropeanPatent No.2,099,765This patent covers several newisoquinolinamine compounds andtheir pharmaceutical compositionand method for producing an antitumoreffect.International StemCell CorporationOTCQB: ISCOA developmental stage biotechnologycompany focusedon the development and commercializationof therapeutic,biomedical, and cosmeceuticalproductsU.S. Patent andTrademark OfficeU.S. Patent No.8,268,621The patent covers a method of creatingpure populations of definitiveendoderm, precursor cells to liverand pancreas cells, from humanpluripotent stem cells.Aegis Therapeutics Private A drug delivery technologycompany commercializing itspatented drug delivery anddrug formulation technologiesthrough product-specificlicensesU.S. Patent andTrademark OfficeU.S. Patent No.8,268,791The patent covers fast actingformulations for triptans, a classof drugs that are effective in treatingmigraine headaches whichinclude sumatriptan, zolmitriptan,naratriptan, rizatriptan, eletriptan,almotriptan and frovatriptan.Dyadic International OTC Pink: DYAI A global biotechnology companythat uses its patentedand proprietary technologiesto conduct research,development and commercialactivities for the discovery,development, manufactureand sale of enzymes and otherproteins for the bioenergy,bio-based chemical, biopharmaceuticaland industrialenzyme industriesU.S. Patent andTrademark OfficeU.S. Patent No.8,268,585The inventions embodied bythis patent describe methods ofdeveloping, programming andgrowing improved strains of thefungal microorganisms which makeup Dyadic’s C1 platform technology.The patent claims cover theconstruction and use of C1 strainsfor the economical over-productionof enzymes and other proteins atindustrial scale for a broad numberof applications.Aeterna Zentaris Nasdaq: AEZS An oncology and endocrinologydrug development companycurrently investigatingtreatments for various unmetmedical needsEuropean PatentOfficeEuropeanPatent No.1,984,744The patent is for the use of theghrelin agonist, AEZS-130, relatedto methods and kits for use inrelation to the diagnosis of growthhormone deficiency in a human oranimal subject.(continued) ❱❱November 2012 44